corporate profile

Novocure (NASDAQ: NVCR) is a global oncology company striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of our innovative therapy, Tumor Treating Fields (TTFields). Our commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma (GBM) and for the treatment of adult patients with malignant pleural mesothelioma (MPM). In the U.S., our GBM therapy is approved by the U.S. Food and Drug Administration (FDA) under the Premarket Approval (PMA) pathway, and our MPM therapy is approved by the FDA under the Humanitarian Device Exemption (HDE) pathway. We continue to explore the safety and efficacy of TTFields for the treatment of multiple solid tumor cancers of the brain, thorax and abdomen.

corporate presentation clinical evidence
3
FDA-approved indications
27,000+
patients treated through January 2023
$538M
annual net revenues (2022)
$206M
annual R&D investments (2022)
4
phase 3 trials in new indications
view all

latest filings

date filing type filing download
November 28, 2023 8-K Current report filing
November 09, 2023 SC 13G/A Amended Statement of Ownership
November 08, 2023 4 Statement of Changes in Beneficial Ownership
November 03, 2023 4 Statement of Changes in Beneficial Ownership
November 02, 2023 3 Initial Statement of Beneficial Ownership
November 02, 2023 4 Statement of Changes in Beneficial Ownership
October 26, 2023 8-K Current report filing
October 26, 2023 10-Q Quarterly Report
September 05, 2023 4 Statement of Changes in Beneficial Ownership
September 05, 2023 4 Statement of Changes in Beneficial Ownership
September 05, 2023 4 Statement of Changes in Beneficial Ownership
September 01, 2023 144 Report of proposed sale of securities
August 28, 2023 8-K Current report filing
August 04, 2023 4 Statement of Changes in Beneficial Ownership
July 27, 2023 8-K Current report filing
mission, vision and values

mission

Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer by developing and commercializing our innovative therapy.

vision

Patient-forward: aspiring to make a difference in cancer

learn more

contact us

investorinfo@novocure.com
610-723-7427

sign up for email alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

"*" indicates required fields

List
This field is for validation purposes and should be left unchanged.